Fludarabine, alemtuzumab extended PFS by 7 months in CLL | HemOncToday
Links shared publicly online about this topic.
- 0total visits
Fludarabine, alemtuzumab extended PFS by 7 months in CLL | HemOncToday
Fludarabine combined with alemtuzumab improved PFS for patients with chronic lymphocytic leukemia compared with fludarabine alone, according to
View full resource at hemonctoday.com
Tags: Leukemia, Chronic Lymphocytic Leukemia
Most Recently Shared on October 12, 2011 at 8:36 pm By:
#Fludarabine, #alemtuzumab extended PFS by 7 months in CLL http://t.co/7rqW7TQK
Advertisement
